These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 15830280)
1. A case of encapsulating peritoneal sclerosis at the clinical early stage with high concentration of matrix metalloproteinase-2 in peritoneal effluent. Masunaga Y; Hirahara I; Shimano Y; Kurosu M; Iimura O; Miyata Y; Amemiya M; Homma S; Kusano E; Asano Y Clin Exp Nephrol; 2005 Mar; 9(1):85-9. PubMed ID: 15830280 [TBL] [Abstract][Full Text] [Related]
2. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis--a multicentre study in Japan. Hirahara I; Inoue M; Okuda K; Ando Y; Muto S; Kusano E Nephrol Dial Transplant; 2007 Feb; 22(2):560-7. PubMed ID: 17035369 [TBL] [Abstract][Full Text] [Related]
4. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033 [TBL] [Abstract][Full Text] [Related]
5. An emerging and devastating acute abdomen in a patient under peritoneal dialysis: encapsulating peritoneal sclerosis. Lin HC; Wang RF; Chen CC; Wang TL; Chong CF Am J Emerg Med; 2008 Feb; 26(2):245.e3-4. PubMed ID: 18272118 [TBL] [Abstract][Full Text] [Related]
6. High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment. Yamamoto R; Nakayama M; Hasegawa T; Miwako N; Yamamoto H; Yokoyami K; Ikeda M; Kato N; Hayakawa H; Takahashi H; Otsuka Y; Kawaguchi Y; Hosoya T Adv Perit Dial; 2002; 18():131-4. PubMed ID: 12402604 [TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase levels in the drained dialysate reflect the peritoneal solute transport rate: a multicentre study in Japan. Hirahara I; Inoue M; Umino T; Saito O; Muto S; Kusano E Nephrol Dial Transplant; 2011 May; 26(5):1695-701. PubMed ID: 20921293 [TBL] [Abstract][Full Text] [Related]
10. Risk factors and preventive measures for encapsulating peritoneal sclerosis--Jikei experience 2002. Nakayama M; Yamamoto H; Ikeda M; Hasegawa T; Kato N; Takahashi H; Otsuka Y; Yokoyama K; Yamamoto R; Kawaguchi Y; Hosoya T Adv Perit Dial; 2002; 18():144-8. PubMed ID: 12402607 [TBL] [Abstract][Full Text] [Related]
11. Histologic criteria for diagnosing encapsulating peritoneal sclerosis in continuous ambulatory peritoneal dialysis patients. Honda K; Nitta K; Horita S; Tsukada M; Itabashi M; Nihei H; Akiba T; Oda H Adv Perit Dial; 2003; 19():169-75. PubMed ID: 14763056 [TBL] [Abstract][Full Text] [Related]
12. Reversible peritoneal calcification in a patient treated by CAPD. Kitoh C; Miyagi K; Onoe T; Katano K; Shimada T; Takegoshi T Clin Nephrol; 1999 Nov; 52(5):329-32. PubMed ID: 10584998 [TBL] [Abstract][Full Text] [Related]
13. Encapsulating peritoneal sclerosis in patients on peritoneal dialysis. Hendriks MP; de Sévaux RG; Hilbrands LB Neth J Med; 2008; 66(7):269-74. PubMed ID: 18663253 [TBL] [Abstract][Full Text] [Related]
14. Peritoneal rest may successfully recover ultrafiltration in patients who develop peritoneal hyperpermeability with time on continuous ambulatory peritoneal dialysis. Rodrigues A; Cabrita A; Maia P; Guimarães S Adv Perit Dial; 2002; 18():78-80. PubMed ID: 12402593 [TBL] [Abstract][Full Text] [Related]
15. Fifteen cases of encapsulating peritoneal sclerosis related to peritoneal dialysis: a single-center experience in Japan. Yamamoto H; Nakayama M; yamamoto R; Otsuka Y; Takahashi H; Kato N; Hayakawa H; Hasegawa T; Ikeda M; Yokoyama K; Kawaguchi Y; Mukai H; Hosoya T Adv Perit Dial; 2002; 18():135-8. PubMed ID: 12402605 [TBL] [Abstract][Full Text] [Related]
16. What does the dialysate level of matrix metalloproteinase 2 tell us? Ertilav M; Timur O; Hür E; Bozkurt D; Nar H; Kologlu T; Sen S; Duman S Adv Perit Dial; 2011; 27():6-10. PubMed ID: 22073820 [TBL] [Abstract][Full Text] [Related]
17. [Encapsulating peritoneal sclerosis as a serious complication of peritoneal dialysotherapy--current opinions on treatment and prevention]. Baczyński D; Antosiewicz S; Wańkowicz Z Pol Merkur Lekarski; 2004 Aug; 17(98):168-70. PubMed ID: 15603330 [TBL] [Abstract][Full Text] [Related]
18. Treatment options for encapsulating peritoneal sclerosis based on progressive stage. Kawanishi H; Harada Y; Noriyuki T; Kawai T; Takahashi S; Moriishi M; Tsuchiya S Adv Perit Dial; 2001; 17():200-4. PubMed ID: 11510276 [TBL] [Abstract][Full Text] [Related]
19. Localization and extent of peritoneal calcification in three uremic patients on continuous ambulatory peritoneal dialysis. Dejima K; Mitsuhashi H; Yasuda G; Hirawa N; Ikeda Y; Umemura S Ther Apher Dial; 2008 Oct; 12(5):413-6. PubMed ID: 18937728 [TBL] [Abstract][Full Text] [Related]
20. [Long-standing high-transport membrane as a risk factor for EPS development after PD withdrawal: an analysis based on changes in peritoneal function during and after CAPD withdrawal]. Nakayama M; Ikeda M; Katoh N; Hayakawa H; Numata M; Otsuka Y; Yamamoto R; Yamamoto H; Yokoyama K; Kubo H; Kawaguchi Y; Hosoya T Nihon Jinzo Gakkai Shi; 2002 May; 44(4):396-401. PubMed ID: 12073625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]